Top Markets
#1 GEKKO GEKKO +52.86%
#2 TENDIES TENDIES +48.87%
#3 Helium Helium +46.85%
#4 Pons Pons +41.91%
#5 ADO Protocol ADO Protocol +39.18%
#6 Prom Prom +33.01%
#7 Collector Crypt Collector Crypt +20.14%
#8 Nillion Nillion +19.44%
#9 龙虾 (Lobster) 龙虾 (Lobster) +18.52%
#10 o1.exchange o1.exchange +18.40%
Coin of the day
GEKKO GEKKO
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Provention Bio, Inc. Provention Bio, Inc.

Provention Bio, Inc.

PRVB
Classifica tra le azioni #9449
Provention Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Provention Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and bringing to market therapies aimed at intercepting and preventing autoimmune disorders. Their lead investigational candidate, PRV-031 (teplizumab, a monoclonal antibody), is currently in a Phase III clinical trial for the interception of Type 1 Diabetes (T1D). Another asset, PRV-3279, has successfully completed its Phase Ib clinical trial for the treatment of lupus. The company is also developing PRV-101, a vaccine targeting coxsackie virus B (CVB) to prevent both acute CVB infections and the onset of T1D. Additionally, PRV-015 is undergoing a Phase IIb clinical trial, offering a potential treatment for celiac disease that does not respond to a gluten-free diet. Provention Bio has established strategic partnerships to advance its pipeline. This includes a licensing and collaboration agreement with Amgen Inc. for PRV-015, described as a novel anti-IL-15 monoclonal antibody, for the continued development against gluten-free diet non-responsive celiac disease. Furthermore, a strategic alliance with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. focuses on the development and commercialization of PRV-3279 in Greater China. PRV-3279 is characterized as a bispecific antibody-based molecule designed to target B cell surface proteins CD32B and CD79B. Founded in 2016, Provention Bio, Inc. maintains its headquarters in Red Bank, New Jersey.
Prezzo delle azioni
$24.98
Ultima sincronizzazione: 2023-04-27
Capitalizzazione di mercato
$1.01B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Provention Bio, Inc. (PRVB)

Categoria

Healthcare
Storico del prezzo dell'azione per Provention Bio, Inc. (PRVB)
Prezzo di chiusura più alto: $24.40 il 2023-04-01

Prezzo di chiusura più basso: $4.34 il 2018-07-01
Storico del prezzo dell'azione di Provention Bio, Inc. dal 2018 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2023 158.40%
2022 53.04%
2021 -64.36%
2020 44.04%
2019 443.29%
2018 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $542.09 38.63%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.03K 44.13%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.53 -12.70%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $138.18 473.58%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $759.27 7.20%
CH